SCHEMBL24310086

SCHEMBL24310086

Cc1cccc(C)c1-c1cc(Oc2ccc(Br)cc2)nc(NS(=O)(=O)c2cnn(C)c2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.40
▸ TSHR P16473 2/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ MET P08581 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ BRD4 O60885 2/20 0.35
▸ PIK3CD O00329 1/20 0.35
▸ PIK3CB P42338 1/20 0.35
▸ MTOR P42345 1/20 0.35
▸ PIK3CG P48736 1/20 0.35
▸ HTR1A P08908 4/20 0.34
▸ HTR7 P34969 4/20 0.34
▸ PGR P06401 1/20 0.33
▸ HPGD P15428 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ PTGS1 P23219 1/20 0.32
▸ PTGS2 P35354 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566748 1.00 GAA (0.40) GAATSHRSMN1; SMN2METKDR
SCHEMBL26810238 0.92 SMN1; SMN2 (0.38) TSHRSMN1; SMN2METBRD4PIK3CD
SCHEMBL29566612 0.92 TSHR (0.43) GAATSHRSMN1; SMN2KDRBRD4
SCHEMBL24310345 0.92 TSHR (0.43) GAATSHRSMN1; SMN2KDRBRD4
SCHEMBL24309674 0.91 TSHR (0.37) GAATSHRSMN1; SMN2KDRBRD4
SCHEMBL26810218 0.91 KMT2A (0.40) GAATSHRSMN1; SMN2METKDR
SCHEMBL26857058 0.90 TSHR (0.36) TSHRSMN1; SMN2KDRBRD4PIK3CD
SCHEMBL26810050 0.90 HTR1A (0.42) TSHRSMN1; SMN2KDRBRD4PIK3CD
SCHEMBL24310039 0.88 GFER (0.39) TSHRSMN1; SMN2KDRHTR1AHTR7
SCHEMBL29566838 0.88 GFER (0.39) TSHRSMN1; SMN2KDRHTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B GAA 904/4885TSHR 1755/4885SMN1; SMN2 4847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback